Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma.
* Retinoblastoma is the most common intraocular malignant childhood
tumor in need of prospective clinical trials to address important
unanswered questions about biology, treatment, and prognostic factors.
Currently, there is controversy about the definitions for choroidal
invasion and an inconsistency in the handling of eyes with
retinoblastoma. The International Retinoblastoma Staging Working Group
(IRSWG) composed of 58 participants from 24 countries on 4 continents
had a series of Internet meetings to discuss the staging and tissue
handling guidelines to reach consensus for adequate processing,
establishing definitions of histopathologic risk factors, and reporting
of enucleated eyes with retinoblastoma to serve as the basis for
clinical trials and studies to validate the proposed criteria. The
meetings were facilitated by the International Outreach Program of the
St. Jude Children's Research Hospital through Cure4Kids. The
retinoblastoma guidelines from the Children's Oncology Group, the
French Society for Pediatric Cancers, the Association of Directors of
Anatomic and Surgical Pathology, and some published data were the basis
for this consensus document. Discussions of the feasibility,
practicality, and efficacy of the guidelines and criteria resulted in
this report. The consensus definitions reached included definition of
massive choroidal invasion stated as a maximum diameter of invasive
tumor focus of 3 mm or more that may reach the scleral tissue. Focal
choroidal invasion is defined as a tumor focus of less than 3 mm and not
reaching the sclera. Optic nerve invasion is classified as prelaminar,
laminar, retrolaminar, or tumor at surgical margin, and the measurement
of the depth of invasion should also be recorded. These guidelines also
address handling of the enucleated eye with retinoblastoma in an
efficient, practical, and feasible manner for a meaningful diagnosis.
The consensus criteria reached by the IRSWG should be validated through
prospective clinical trials and studies.
(Arch Pathol Lab Med. 2009;133:1199-1202)
Retinoblastoma (Care and treatment)
Cancer in children (Diagnosis)
Cancer in children (Risk factors)
Cancer in children (Care and treatment)
Histology, Pathological (Research)
Clinical pathology (Research)
Chantada, Guillermo L.
Wilson, Matthew W.
de Davila, Maria T.G.
|Publication:||Name: Archives of Pathology & Laboratory Medicine Publisher: College of American Pathologists Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 College of American Pathologists ISSN: 1543-2165|
|Issue:||Date: August, 2009 Source Volume: 133 Source Issue: 8|
|Topic:||Event Code: 310 Science & research|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Retinoblastoma--the most frequent primary intraocular tumor in
children--lacks validation of a number of prognostic factors and
requires a consensus on criteria for processing and interpreting
histopathologic features. This is unlike uveal melanoma--the most
frequent primary intraocular tumor in adults--in which histopathologic
and molecular prognostic factors have been identified and validated
through large retrospective and prospective studies and by molecular
genetic assays. The current era of utilization of chemoreduction and
adjuvant chemotherapy for retinoblastoma has prompted the need to
standardize criteria across institutions and countries. However, there
is scant literature available with clinical relevance and with
prospective studies validating the indications for different
chemotherapeutic approaches, especially adjuvant therapy. (1-13) To
address this problem, a group of experts from around the world formed by
the International Retinoblastoma Staging Working Group (IRSWG), (6,8)
composed of 58 participants from 24 countries on 4 continents, held
regular Internet Web-based consensus conferences to agree upon the
recommendations to initiate a systematic validation of prognostic
factors in eyes with retinoblastoma. The results of the consensus
meetings are the subject of this communication and are the proposed
basic processing techniques for obtaining best results in harvesting
tissue for molecular studies and preservation of important
histopathologic markers and for standardizing criteria for evaluation of
high risk factors in enucleated eyes with retinoblastoma. The
recommendations of the group, although representing a solid starting
point, need to be prospectively validated through clinical trials and
[FIGURE 1 OMITTED]
The meetings of the IRSWG were facilitated by the International Outreach Program of the St. Jude Children's Research Hospital in Memphis, Tennessee, through Cure4Kids. The retinoblastoma guidelines from the Children's Oncology Group, the French Society for Pediatric Cancers, the Association of Directors of Anatomic and Surgical Pathology, and the limited literature available related to the topic were the basis for this consensus document. (1-13) The discussions were focused on the feasibility, practicality, and efficacy of the proposed guidelines and on criteria based on the experience of the participants in different socioeconomic settings.
PROPOSED CONSENSUS CRITERIA
Consensus was reached for definitions of choroidal invasion. The proposed criteria to diagnose massive or significant choroidal invasion is when the maximum diameter (thickness or width) of invasive focus of tumor measures 3 mm or more in any diameter and, additionally, as a helpful landmark, when most of these tumors reach at least the inner fibers of the scleral tissue (Figure 1, a). The proposed criteria for focal choroidal invasion are defined as a tumor focus of less than 3 mm in any diameter (thickness or width) and not reaching the sclera (Figure 1, b). The group also discussed the importance of recognizing artifactual tumor seeding of the choroid and other extraocular tissues during fresh tumor retrieval to avoid overdiagnosing choroidal invasion. Artifactual seeding is composed of small groups of tumor cells, usually with many necrotic cells present inside natural spaces of the eye (eg, vascular choroidal and suprachoroidal space, anterior chamber, or subarachnoid space of the optic nerve), spaces created by sectioning artifacts, and/or on the surfaces of the eye (episclera, over meninges of optic nerve, and soft tissues attached to optic nerve). In contrast, true tumor invasion is composed of solid nests of tumor that have usually pushed or infiltrating borders, expanding and replacing the area of invasion. They typically lack necrosis, unless the tumor is extremely large.
The consensus for optic nerve invasion includes classification as prelaminar, laminar, retrolaminar, or tumor at surgical margin. The focus of tumor invasion should also be measured. To obtain the maximum depth of invasion into the optic nerve, the tumor should be measured from the level of the limiting membrane of the optic disc, the exit of the large central vessels, or, if none of these structures are preserved, from the level of the Bruch membrane to the deepest site of invasion (Figure 1, c).
The third part of the consensus was the agreement about the proposed guideline addressing processing of the enucleated eye with retinoblastoma to obtain best histopathologic results and fresh tumor for molecular testing. Two basic techniques were proposed to safely retrieve tumor without extensive contamination of ocular structures by tumor. Basically, the enucleated eye should be open immediately after the surgery to avoid denaturation of nucleic acids and proteins. The optic nerve should be measured for length and the cut margin should be obtained before opening the eye. The first technique proposed is the opening of a window in the sclera at the edge of the area containing most of the tumor. The window may be obtained using a trephine (corneal [for grafts]) or by using a sharp blade (Figure 2, a through c). Fresh tumor then should be retrieved from areas without necrosis. The other technique proposed is the aspiration of tumor by using a large bore needle by the introduction (under sterile conditions) of a 22-gauge needle through the sclera posteriorly to the lens according to a slightly oblique anteroposterior course under visual control (Figure 2, d). When the needle is situated in the tumor, tumor material is aspirated by connecting a syringe to the needle. In the case of a nonfriable tumor, a few milliliters of culture medium can be introduced, allowing dilution of the tumor material and facilitating aspiration. When the material has been collected, an aliquot may be analyzed to evaluate the tumor cellularity of the aspirate. After tumor harvesting by both techniques, the eye is then placed in sufficient formalin to cover the globe and fixed for at least 48 hours.
[FIGURE 2 OMITTED]
Consensus was reached as to the examination of the entire eye microscopically by submitting a total of 4 blocks. One block is the central pupil-optic nerve (PO) section containing the optic nerve, tumor, and anterior chamber structures (Figure 3, a). Two blocks will contain the calottes (remainder of ocular tissue after obtaining the PO) in anterior-posterior segments embedded on edge to examine more choroidal surface (Figure 3, b). The fourth block contains the cross section of the margin of the optic nerve, obtained before opening the eye. The slides of the PO section should contain the optic nerve head, lamina cribrosa, and postlaminar optic nerve in a single plane of section (Figure 3, c).
The proposed guidelines for definitions of high-risk features and for processing of the eyes with retinoblastoma are based on the previous reports and experiences of experts around the world and were felt to be practical, feasible, and objective. Prospective clinical trials and other studies must validate the proposed consensus criteria.
[FIGURE 3 OMITTED]
Accepted for publication April 23, 2009.
(1.) Abramson DH. Retinoblastoma incidence in the United States. Arch Ophthalmol. 1990;108:1514.
(2.) Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004;24: 828-848.
(3.) Zucker JM, Desjardins L, Doz F. Retinoblastoma [discussion in Eur J Cancer. 1998;34:1048-1049]. Eur J Cancer. 1998;34:1045-1048.
(4.) Antoneli CB, Steinhorst F, de Cassia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292-1298.
(5.) Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2000;37(3):134-141.
(6.) Chantada GL, Doz F, Orjuela M, et al; for the International Retinoblastoma Staging Working Group. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2007;50(3):692-694.
(7.) Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120:923-931.
(8.) Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthal mol. 2004;88:1069-1073.
(9.) Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1 996;77:1206-1213.
(10.) Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factors. Cancer. 1994;73:692-698.
(11.) Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96:217-222.
(12.) Chantada GL, Dunkel IJ, Antoneli CB, et al. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. Pediatr Blood Cancer. 2007;49(3):256-260.
(13.) Chong EM, Coffee RE, Chintagumpala M, Hurwitz RL, Hurwitz MY, Chevez-Barrios P. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med. 2006;130(11):1669-1672.
Xavier Sastre, MD; Guillermo L. Chantada, MD; Francois Doz, MD; Matthew W. Wilson, MD; Maria T. G. de Davila, MD, PhD; Carlos Rodriguez-Galindo, MD; Murali Chintagumpala, MD; Patricia Chevez-Barrios, MD; for the International Retinoblastoma Staging Working Group
From Pathology, Institut Curie, Paris, France (Dr Sastre); Hemato-Oncology Service (Dr Chantada) and the Department of Pathology (Dr de Davila), Hospital JP Garrahan, Buenos Aires, Argentina; the Department of Pediatric Oncology, Institut Curie and Facultede Medecine Paris Descartes, Paris, France (Dr Doz); Hamilton Eye Institute, Department of Ophthalmology, University of Tennessee Health Science Center and the Department of Surgery, Division of Ophthalmology, and Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (Dr Wilson); the Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (Dr Rodriguez-Galindo); the Department of Pediatrics, Texas Children's Cancer Center and Baylor College of Medicine, Houston, Texas (Dr Chintagumpala); and the Department of Pathology, Weil Medical College of Cornell University, New York, New York, the Department of Ophthalmology, Baylor College of Medicine, the Department of Pathology, University of Texas, M. D. Anderson Cancer Center, and Ophthalmic Pathology Program, The Methodist Hospital, The Methodist Hospital Research Institute, Houston, Texas (Dr Chevez-Barrios).
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Patricia Chevez-Barrios, MD, Ophthalmic Pathology Program, The Methodist Hospital, 6565 Fannin Street, M22 7, Houston, TX 77030 (e-mail: firstname.lastname@example.org).
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|